AbCellera

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
Thursday, May 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

AbCellera Reports Full Year 2023 Business Results

Retrieved on: 
Tuesday, February 20, 2024
Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Research and development, Investment, Growth, S&M, AbCellera, Webcast, Administration, G&A, IND, Research, Partnership, Pharmaceutical industry

AbCellera started discovery on an additional twelve partner-initiated programs with downstreams to reach a cumulative total of 87 partner-initiated program starts with downstreams in 2023 (up from 75 on December 31, 2022).

Key Points: 
  • AbCellera started discovery on an additional twelve partner-initiated programs with downstreams to reach a cumulative total of 87 partner-initiated program starts with downstreams in 2023 (up from 75 on December 31, 2022).
  • The partnership business generated research fees of $35.6 million, compared to $40.8 million in 2022.
  • Revenue for the fourth quarter of 2023 was $9.2 million, representing 24% of total revenue for 2023.
  • AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Science, Conference, Geographic atrophy, Food, GMG, Risk, Woman, EMA, Paratriathlon, Data, Injection site reaction, AbCellera, HPP, Antiphospholipid syndrome, European Medicines Agency, Pregnancy, Corporation, DSM-IV codes, C5, Hypophosphatasia, ENPP1, Investment, Webcast, Patient, Therapy, Pharmaceutical industry

Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.

Key Points: 
  • Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.
  • Rallybio expects to complete this manufacturing work and provide an update on the development plan for RLYB116 in the second half of 2024.
  • Rallybio and EyePoint expect to provide an update on this collaboration in the first half of 2024.
  • Rallybio and Exscientia plan to provide an update on the progress of the program in the second half of 2024.

AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Biometrics, Health, Pharmaceutical, Health Technology, ABCL, Conference, Piper Sandler Companies, Nightclub, Broadcasting, AbCellera

AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).

Key Points: 
  • AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).
  • A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website .
  • A replay will be available through the same link following the presentation.

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Survival, Research, Standard of care, Research and development, Plasma, AACR, IV, Antigen, MCL1, SMARCA4, MD, G&A, SMARCA2, Conference, Hematological Cancer Research Investment and Education Act, Chromatin, CDK9, MYC, Protein, AbCellera, R, Growth, Cell death, Antibody, Partnership, Spacecraft, Cancer, Hepatotoxicity, Security (finance), Brain, Bone marrow, Toxicity, Safety, Lymphoid leukemia, Patient, EU, Administration, Neutropenia, AML, Mutation, Prelude, Pharmaceutical industry, Vaccine, Fine chemical, IND, PRB

WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.

Key Points: 
  • Given the overlap with the CDK9 program, Prelude does not plan to advance PRT1419 further at this time.
  • Given the focus of the Company on SMARCA2 and CDK9, Prelude will not advance the program further and is actively pursuing further clinical development with external partners.
  • “We made significant progress in the third quarter with our four clinical stage molecules and, as planned, conducted a rigorous assessment of each program.
  • We expect our R&D expenses to vary from quarter to quarter, primarily due to the timing of our clinical development activities.

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Retrieved on: 
Wednesday, November 1, 2023
ABCL, SMARCA2, AbCellera, ADC, Antibody, Partnership, Spacecraft, Cancer, Patient, Prelude, Fine chemical, Pharmaceutical industry

& VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.

Key Points: 
  • & VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.
  • The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera’s antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs).
  • “Through this strategic partnership we are combining deep expertise in antibody and small molecule development to create precision ADC therapies for patients in need,” said Carl Hansen, Ph.D., Founder and CEO of AbCellera.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Retrieved on: 
Wednesday, November 1, 2023
Research, Biotechnology, Biometrics, Other Health, Health, General Health, Other Science, Science, Oncology, ABCL, Cancer, ADC, SMARCA2, Patient, Antibody, Multimedia, Spacecraft, Partnership, AbCellera, Prelude, Fine chemical, Pharmaceutical industry

Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.

Key Points: 
  • Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD) and AbCellera (Nasdaq: ABCL) today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients with cancer.
  • The collaboration combines Prelude’s expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera’s antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs).
  • “Through this strategic partnership we are combining deep expertise in antibody and small molecule development to create precision ADC therapies for patients in need,” said Carl Hansen, Ph.D., Founder and CEO of AbCellera.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, ABCL, TCE, CD3, Therapy, Society for Immunotherapy of Cancer, Poster, SITC, Immunotherapy, Risk, Biology, Cytokine release syndrome, Trichloroethylene, Annual general meeting, Society, PSMA, Patient, Translation, Vaccine, AbCellera

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) programs in two poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.
  • The data illustrate how AbCellera is leveraging its TCE platform to discover and develop immuno-oncology therapeutics for multiple tumor targets.
  • In its first poster, AbCellera presented data demonstrating that TCE function is determined by multiple factors, including—but not limited to—CD3-binding affinity.
  • The poster included data from two of these programs targeting prostate-specific membrane antigen (PSMA) and melanoma-associated antigen 4 (MAGE-A4).